# OnCo record nct03182244 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03182244/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03182244", "NCT03182244" ;
  schema:name "A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation"@en ;
  schema:description "A phase 3 trial of Gilteritinib, Cytarabine, Mitoxantrone, Etoposide and Fludarabine in acute myeloid leukaemia, run by Astellas Pharma Inc, now completed."@en ;
  schema:url <https://onco.cc/trials/nct03182244/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03182244> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2017-10-25" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-flt3/> ;
  onco:drugs <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/mitoxantrone/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/fludarabine/> ;
  onco:companies <https://onco.cc/companies/astellas/> .